Mixed connective tissue disease (MCTD) is a systemic autoimmune disease characterized by overlapping features of systemic lupus erythematosus, systemic sclerosis, and inflammatory muscle disease, together with antibodies against U1 ribonucleoprotein (U1-RNP). Common manifestations include Raynaud phenomenon, swollen hands, inflammatory joint symptoms, and muscle weakness. The clinical pattern varies between individuals and can change over time. Lung and pulmonary blood-vessel involvement are particularly important determinants of disease severity.
Biological basis
MCTD involves abnormal immune responses directed against the body’s own cellular components. Its characteristic laboratory finding is anti-U1-RNP, an antibody directed against proteins associated with U1 small nuclear ribonucleoprotein, a complex involved in processing RNA.
Anti-U1-RNP antibodies are often present at high levels, but they are not exclusive to MCTD: they also occur in lupus and other systemic autoimmune disorders. Their presence therefore supports the diagnosis only when interpreted alongside characteristic clinical findings.
The cause of MCTD is not established. Genetic susceptibility and environmental influences are thought to contribute, but no single trigger explains the disease. Its manifestations involve varying combinations of inflammation, small-vessel dysfunction, and fibrosis, or excessive connective-tissue scarring.
Clinical manifestations
Features may develop gradually rather than appearing together at disease onset.
Blood vessels and skin
Raynaud phenomenon is a frequent early manifestation. Episodes of reduced blood flow to the fingers or toes cause color changes, often in response to cold or emotional stress. Puffy fingers or swollen hands are also characteristic. Some people develop tightening of the skin over the fingers, fingertip ulcers, or lupus-like skin eruptions.
Joints and muscles
Joint pain, stiffness, and inflammatory arthritis are common. The arthritis can resemble rheumatoid arthritis and is occasionally erosive.
Inflammatory myopathy can cause weakness, particularly around the shoulders and hips. Muscle enzymes may be elevated, although the degree of weakness and laboratory abnormalities varies. Fatigue and muscle discomfort can occur with or without demonstrable muscle inflammation.
Lungs and pulmonary circulation
Two major complications are:
- Interstitial lung disease, in which inflammation and scarring affect the tissue surrounding the lung’s air sacs.
- Pulmonary hypertension, including pulmonary arterial hypertension, in which elevated pressure in the pulmonary circulation places strain on the right side of the heart.
Both can cause exertional breathlessness and reduced exercise tolerance. They are distinct conditions, although they can coexist. Pulmonary hypertension in MCTD may arise through more than one mechanism, so determining its cause is important.
Other organs
Abnormal movement of the esophagus can cause swallowing difficulties and gastroesophageal reflux. Inflammation of the lining around the heart or lungs may occur. Blood abnormalities include anemia and reduced white blood cell or platelet counts.
Kidney and nervous-system involvement are possible. Severe kidney disease is less characteristic than in some forms of lupus, but its absence is not a defining requirement.
Diagnosis and classification
Diagnosis combines clinical findings, antibody testing, and assessment of affected organs. No single symptom or laboratory result establishes MCTD.
An antinuclear antibody test is commonly positive, often with a speckled pattern. Testing for anti-U1-RNP is central to assessment, but a positive result alone does not distinguish MCTD from lupus or another autoimmune disorder. Antibody levels do not provide a reliable stand-alone measure of disease activity.
Several classification systems have been proposed, including the Sharp, Alarcón-Segovia, Kasukawa, and Kahn criteria. They differ in their required combinations of antibody findings and clinical manifestations. Classification criteria help define research populations but do not replace clinical judgment.
Investigations depend on the presentation. They may include blood counts, muscle enzymes, kidney-function tests, urinalysis, pulmonary-function testing, echocardiography, and high-resolution chest computed tomography. Right-heart catheterization is used to confirm pulmonary hypertension and characterize its hemodynamic type.
The differential diagnosis includes lupus, systemic sclerosis, inflammatory myopathies, rheumatoid arthritis, other overlap syndromes, and undifferentiated connective tissue disease. Reassessment over time can clarify an initially incomplete clinical pattern.
Treatment
Treatment is directed at the manifestations and organs involved rather than at the antibody result alone. There is no single regimen appropriate for every person with MCTD.
Nonsteroidal anti-inflammatory drugs and hydroxychloroquine are used for some joint and skin manifestations. Corticosteroids and other immunosuppressive medicines are used for inflammatory organ involvement. Selection depends on severity, affected organs, coexisting conditions, and treatment risks.
Raynaud phenomenon may be treated with vasodilator medicines. Interstitial lung disease may require immunosuppressive treatment, while pulmonary arterial hypertension may require therapies targeting the pulmonary circulation. These complications require different assessments and treatment approaches.
Evidence specific to MCTD is limited. Much treatment practice is informed by studies of related connective tissue diseases and by the particular organ manifestation being treated, rather than by large MCTD-specific randomized controlled trials.
Epidemiology, history, and course
MCTD is uncommon and occurs more often in women than in men. It can occur in children and adults. Reported frequency varies with the population studied and the classification criteria used, limiting comparisons between estimates.
The syndrome was described by Gordon Sharp and colleagues in 1972 in patients with overlapping rheumatic manifestations and a characteristic antibody profile. Its clinical boundaries remain imperfectly standardized: some individuals retain a recognizable MCTD pattern, while others later meet criteria for another connective tissue disease.
The course ranges from relatively limited joint, skin, and vascular manifestations to serious multisystem disease. Interstitial lung disease and pulmonary hypertension are major contributors to illness and mortality. Long-term assessment distinguishes reversible inflammatory activity from established organ damage and identifies changes in the pattern of organ involvement.